Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

NCT02877550 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02877550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02877550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
February 15, 2017
Completion date
May 4, 2022
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma